Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for Cardiologist

Cardiomyopathies Clinical Trial

— TARIFF  

Official title:

Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for Cardiologist

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02883205
• Other study ID #: 15-060
• Status: Recruiting
• Phase: N/A
• First received: August 25, 2016
• Last updated: August 25, 2016
• Start date: January 2015
• Est. completion date: December 2016

Study information

• Verified date: August 2016
• Source: University Hospital, Caen
• Contact: Fabien Labombarda, MD
• Phone: 611238306
• Email: labombarda-f[@]chu-caen.fr
• Is FDA regulated: No
• Health authority: France: Committee for the Protection of Personnes
• Study type: Observational

Clinical Trial Summary

The cardiac Fabry disease are early, frequent and severe, dominated by the frequency of left ventricular hypertrophy. They are responsible for a high morbidity and mortality, reducing life expectancy of 15 to 20 years for men. Fabry disease and heart attacks are still diagnosed late. This delay in diagnosis is due to the non-specificity of clinical, electrocardiographic and echocardiographic disease, but also by a certain ignorance of this pathology in the medical community. The importance of early diagnosis of Fabry disease and heart disease is well established: enzyme replacement therapy is most effective when instituted early, before the onset of irreversible damage such as fibrosis. With the blotter, we now have a simple and robust screening tool for Fabry disease, achievable consultation. Targeted educational interventions to physicians have shown their effectiveness in improving the screening and diagnosis of rare diseases. We offer a prospective observational type before / after study, which aims to assess the value of an educational brochure for cardiologists to improve the screening and diagnosis of Fabry disease in Normandy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with left ventricular hypertrophy of unknown etiology or of sarcomeric MHC pace, followed in Normandy, has given its consent to the search of Fabry disease

Criteria Exclusion:

• Patients under 18 years patient refusal to participate in the study. Lack of consent to the search of Fabry disease

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Cardiomyopathies
• Fabry Disease

Locations

Country	Name	City	State
France	Fabien	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of new cases of Fabry disease diagnosed a year after distribution of educational brochure cardiologists		1 year	No